Filter
1

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

for
Advanced Ovarian Carcinoma,
Location: Boston MA, Mineola NY, New York NY, Bethlehem PA,
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT04575935

Phase3, Recruiting

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

for
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer,
Location: Orange City FL, Clermont FL, Detroit MI, Atlanta GA,
Sponsor: Inhibrx Biosciences, Inc

Sex: All

Age: 18+

Code: NCT04198766

Phase1, Phase2, Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

for
Renal Cell Carcinoma (RCC),
Location: Boston MA, New Haven CT, New York NY, Hackensack NJ,
Sponsor: Exelixis

Sex: All

Age: 18+

Code: NCT05176483

Phase1, Recruiting

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

for
Advanced/Metastatic Solid Tumors, Bladder Cancer,
Location: Boston MA, Newton MA, New Haven CT, Trumbull CT,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07090499

Phase1, Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

for
Cervical Squamous Cell Carcinoma,
Location: New Haven CT, Hackensack NJ, Fairfax VA, Louisville KY,
Sponsor: Alentis Therapeutics AG

Sex: All

Age: 18+

Code: NCT07169734

Phase1, Phase2, Recruiting

Interested in new metastatic urothelial cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

for
Renal Cell Carcinoma, Urothelial Carcinoma,
Location: Boston MA, Philadelphia PA, Cleveland OH, Ann Arbor MI,
Sponsor: Deciphera Pharmaceuticals, LLC

Sex: All

Age: 18+

Code: NCT06966024

Phase1, Recruiting

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

for
Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer,
Location: New York NY, Huntersville NC
Sponsor: GI Innovation, Inc.

Sex: All

Age: 18+

Code: NCT04977453

Phase1, Phase2, Recruiting

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

for
Non Small Cell Lung Cancer,
Location: Boston MA, Austin, TX 78758 TX, San Antonio TX
Sponsor: Zumutor Biologics Inc.

Sex: All

Age: 18+

Code: NCT06451497

Phase1, Recruiting

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

for
Bladder Cancer, Metastatic Bladder Cancer,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 65+

Code: NCT06138561

Recruiting

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

for
Breast Cancer, Gastric Cancer, Esophageal Cancer,
Location: New York NY, Nashville TN, Houston TX, Dallas TX,
Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06695845

Phase2, Recruiting

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

for
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms,
Location: New York NY, East Brunswick NJ, Norfolk VA,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07218380

Phase3, Recruiting

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

for
Kidney Cancer, Renal Cell Carcinoma, Clear Cell Carcinoma,
Location: Dallas TX
Sponsor: University of Texas Southwestern Medical Center

Sex: All

Age: 18+

Code: NCT04623502

Recruiting